Oxytrol oxybutynin patch: Phase III data; NDA under review

WPI said its 3.9 mg/day Oxytrol patch reduced the median number of incontinence episodes per week when compared to placebo (p<0.05), while producing anticholinergic side effects at rates comparable t...